{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:26:13Z","timestamp":1790641573669,"version":"4.1.0"},"reference-count":19,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,6,10]],"date-time":"2024-06-10T00:00:00Z","timestamp":1717977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["kidneymedicinejournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Kidney Medicine"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.xkme.2024.100856","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T20:52:08Z","timestamp":1718398328000},"page":"100856","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases"],"prefix":"10.1016","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2476-1360","authenticated-orcid":false,"given":"Wai Lun Will","family":"Pak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie A.","family":"Brumwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlene C.","family":"Kabel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Gutgarts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Insara","family":"Jaffer Sathick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sham","family":"Mailankody","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander M.","family":"Lesokhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heather J.","family":"Landau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Shaikh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.xkme.2024.100856_bib1","doi-asserted-by":"crossref","first-page":"4691","DOI":"10.1182\/blood-2010-10-299487","article-title":"Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1","volume":"117","author":"Rajkumar","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.xkme.2024.100856_bib2","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene vicleucel in relapsed and refractory multiple myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N\u00a0Engl J Med"},{"issue":"suppl 1","key":"10.1016\/j.xkme.2024.100856_bib3","article-title":"Updated results from CARTITUDE-1: phase 1b\/2Study of Ciltacabtagene Autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed\/refractory multiple myeloma","volume":"138","author":"Martin","year":"2021","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.xkme.2024.100856_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1056\/NEJMoa2213614","article-title":"Ide-cel or standard regimens in relapsed and refractory multiple myeloma","volume":"388","author":"Rodriguez-Otero","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.xkme.2024.100856_bib5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1056\/NEJMoa2303379","article-title":"Cilta-cel or standard care in lenalidomide-refractory multiple myeloma","volume":"389","author":"San-Miguel","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.xkme.2024.100856_bib6","doi-asserted-by":"crossref","first-page":"829 e1","DOI":"10.1016\/j.jtct.2022.09.009","article-title":"Outcomes of CD19-targeted chimeric antigen receptor T cell therapy for patients with reduced renal function including dialysis","volume":"28","author":"Wood","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"1","key":"10.1016\/j.xkme.2024.100856_bib7","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s40164-022-00266-1","article-title":"Successful administration of chimeric antigen receptor (CAR) T-cell therapy in patients requiring hemodialysis","volume":"11","author":"Hunter","year":"2022","journal-title":"Exp Hematol Oncol"},{"issue":"3","key":"10.1016\/j.xkme.2024.100856_bib8","doi-asserted-by":"crossref","first-page":"777","DOI":"10.3324\/haematol.2023.283940","article-title":"Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for relapsed\/refractory multiple myeloma with renal impairment","volume":"109","author":"Sidana","year":"2024","journal-title":"Haematologica"},{"issue":"5","key":"10.1016\/j.xkme.2024.100856_bib9","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1007\/s00277-023-05163-z","article-title":"Safe and successful CAR T-cell therapy targeting BCMA in a multiple myeloma patient requiring hemodialysis","volume":"102","author":"Wasch","year":"2023","journal-title":"Ann Hematol"},{"issue":"7","key":"10.1016\/j.xkme.2024.100856_bib10","doi-asserted-by":"crossref","first-page":"e293","DOI":"10.1016\/S1470-2045(23)00223-1","article-title":"Management of multiple myeloma-related renal impairment: recommendations from the International Myeloma Working Group","volume":"24","author":"Dimopoulos","year":"2023","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100856_bib11","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/0305-7372(95)90010-1","article-title":"Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function","volume":"21","author":"Kintzel","year":"1995","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10.1016\/j.xkme.2024.100856_bib12","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1046\/j.1523-1755.2002.00279.x","article-title":"Cyclophosphamide pharmacokinetics and dose requirements in patients with renal insufficiency","volume":"61","author":"Haubitz","year":"2002","journal-title":"Kidney Int"},{"issue":"8","key":"10.1016\/j.xkme.2024.100856_bib13","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/sj.bmt.1701646","article-title":"Administration and pharmacokinetics of high-dose cyclophosphamide with hemodialysis support for allogeneic bone marrow transplantation in acute leukemia and end-stage renal disease","volume":"23","author":"Perry","year":"1999","journal-title":"Bone Marrow Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2024.100856_bib14","doi-asserted-by":"crossref","first-page":"e229","DOI":"10.1016\/S1470-2045(23)00216-4","article-title":"Dose recommendations for anticancer drugs in patients with renal or hepatic impairment: an update","volume":"24","author":"Giraud","year":"2023","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.xkme.2024.100856_bib15","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.bbmt.2010.04.003","article-title":"Toxic leukoencephalopathy following fludarabine-associated hematopoietic cell transplantation","volume":"17","author":"Beitinjaneh","year":"2011","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.xkme.2024.100856_bib16","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1182\/blood.2019000775","article-title":"Haploidentical hematopoietic cell and kidney transplantation for hematological malignancies and end-stage renal failure","volume":"134","author":"Chen","year":"2019","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.xkme.2024.100856_bib17","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/j.bbmt.2007.08.050","article-title":"Fludarabine-based nonmyeloablative stem cell transplantation for sickle cell disease with and without renal failure: clinical outcome and pharmacokinetics","volume":"13","author":"Horwitz","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"10.1016\/j.xkme.2024.100856_bib18","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1600-0609.2005.00439.x","article-title":"Dialysate concentration and pharmacokinetics of 2F-Ara-A in a patient with acute renal failure","volume":"74","author":"Kielstein","year":"2005","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.xkme.2024.100856_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-022-01301-8","article-title":"Four-year follow-up of LCAR-B38M in relapsed or refractory multiple myeloma: a phase 1, single-arm, open-label, multicenter study in China (LEGEND-2)","volume":"15","author":"Zhao","year":"2022","journal-title":"J\u00a0Hematol Oncol"}],"container-title":["Kidney Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524000670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2590059524000670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T18:16:59Z","timestamp":1723054619000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2590059524000670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":19,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2590059524000670"],"URL":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100856","relation":{},"ISSN":["2590-0595"],"issn-type":[{"value":"2590-0595","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chimeric Antigen Receptor (CAR) T-Cell Therapy Use in Patients with Multiple Myeloma and Kidney Failure on Maintenance Hemodialysis: A Report of 2 Cases","name":"articletitle","label":"Article Title"},{"value":"Kidney Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xkme.2024.100856","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of the National Kidney Foundation, Inc.","name":"copyright","label":"Copyright"}],"article-number":"100856"}}